首页> 美国卫生研究院文献>Infection Chemotherapy >Antibiotic Treatment of Vertebral Osteomyelitis caused by Methicillin-Susceptible Staphylococcus aureus: A Focus on the Use of Oral β-lactams
【2h】

Antibiotic Treatment of Vertebral Osteomyelitis caused by Methicillin-Susceptible Staphylococcus aureus: A Focus on the Use of Oral β-lactams

机译:甲氧西林敏感性金黄色葡萄球菌引起的椎体骨髓炎的抗生素治疗:以口服β-内酰胺类药物为重点

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundVertebral osteomyelitis (VO) is a rare but serious condition, and a potentially significant cause of morbidity. Methicillin-susceptible Staphylococcus aureus (MSSA) is the most common microorganism in native VO. Long-term administration of parenteral and oral antibiotics with good bioavailability and bone penetration is required for therapy. Use of oral β-lactams against staphylococcal bone and joint infections in adults is not generally recommended, but some experts recommend oral switching with β-lactams. This study aimed to describe the current status of antibiotic therapy and treatment outcomes of oral switching with β-lactams in patients with MSSA VO, and to assess risk factors for treatment failure.
机译:背景椎骨骨髓炎(VO)是一种罕见但严重的疾病,可能是发病的重要原因。耐甲氧西林金黄色葡萄球菌(MSSA)是天然VO中最常见的微生物。治疗需要长期服用具有良好生物利用度和骨渗透性的肠胃外和口服抗生素。一般不建议使用口服β-内酰胺类药物治疗成人葡萄球菌骨和关节感染,但一些专家建议使用β-内酰胺类药物进行口服转换。这项研究旨在描述MSSA VO患者的抗生素治疗现状和口服β-内酰胺类药物的治疗结局,并评估治疗失败的危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号